Serina Therapeutics Advances Parkinson’s Trial with Sentinel Dosing Completion
Event summary
- Sentinel dosing in Cohort 1 of Serina’s Phase 1b trial for SER-252 completed, with Safety Monitoring Committee recommending continued dosing.
- Additional patient dosing in Cohort 1 underway at US and Australian sites.
- Cohort 1 enrollment and dosing expected to finish ahead of Q3 2026 guidance.
- SER-252 is designed for advanced Parkinson’s disease, aiming to reduce infusion-based treatment burdens.
The big picture
Serina’s progress with SER-252 reflects broader industry efforts to optimize drug delivery for neurological diseases. The POZ Platform’s ability to extend therapeutic windows could position Serina as a key player in sustained-release formulations, particularly if Phase 1b data supports regulatory advancement.
What we're watching
- Trial Execution Pace
- Whether Serina can sustain the accelerated timeline for Cohort 1 completion.
- Regulatory Pathway
- How early safety data will influence subsequent cohort designs and global site expansions.
- Competitive Positioning
- The potential of SER-252 to differentiate in the Parkinson’s disease treatment landscape.
Related topics